Business
Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update
PUR1900 (Pulmazole) on track for Phase 2 study start in Q1 2023 PUR3100 Phase 1 study top line data anticipated in early Q1 2023 $40.7 million in cash and
About this update from Pulmatrix, Inc.
[{"type":"text","content":"PUR1900 (Pulmazole) on track for Phase 2 study start in Q1 2023\nPUR3100 Phase 1 study top line data anticipated in early Q1 2023\n$40.7 million in cash and cash equivalents at end of Q3 2022\nLEXINGTON, Mass., Nov. 10, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE™ technology, today announced third quarter financial results for 2022 and provided a corporate update related to its development programs.\n\n \n \n \n \n \n \n\n \nTed Raad, Chief Executive Officer of Pulmatrix commented, \"In this quarter we have advanced both PUR3100 and PUR1900 towards important data catalysts. We completed patient dosing for PUR3100, our orally inhaled dihydroergotamine (DHE) being developed for the treatment of acute migraine, in a Phase 1 study with data expected to be released in early Q1 2023. In addition to safety and tolerability, the study will evaluate the pharmacokinetics of PUR3100 compared to intravenous DHE. This will allow us to better understand the potential efficacy and tolerability profile of PUR3100, which we believe could be beneficial to patients suffering from acute migraine. We also commenced study start-up activities for the PUR1900 Phase 2 study and remain on track to initiate patient dosing in the first quarter of 2023. PUR1900 has the potential to be the first approved therapy for the treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in patients with asthma.\"\nThird Quarter 2022 and Recent Program Highlights\nPUR1900 in development for ABPA\nPulmatrix initiated study start-up activities for the Phase 2 safety and efficacy study of PUR1900 in patients with asthma and ABPA. This will include a 16-week dosing regimen and endpoints that would potentially support a Phase 3 trial.PUR3100 in development for acute migraine\nOn September 26, 2022, Pulmatrix announced completion of patient dosing in its Phase 1 trial evaluating PUR3100.Phase 1 study database lock to occur in November with top-line data anticipated to be released in early Q1 2023.PUR1800 in development for Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD)\nPulmatrix is analyzing data from the completed Phase 1b clinical study of PUR1800 for AECOPD for presentation at a relevant medical confere...